Gilead Sciences, Inc. (ETR:GIS)
94.03
+0.22 (0.23%)
Jul 16, 2025, 5:35 PM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B USD in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.39
Revenue / Employee
$1.63M
Employees
17,600
Market Cap
116.83B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.49B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
Gilead Sciences News
- 2 days ago - Gilead twice-yearly HIV prevention drug Yeztugo recommended by WHO - Seeking Alpha
- 2 days ago - Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo) for HIV Prevention at IAS 2025 - Wallstreet:Online
- 2 days ago - Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 - Business Wire
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD - PRNewsWire
- 4 days ago - Gilead Sciences (GILD) Q2 Earnings to Take a Hit from Development Charges - GuruFocus
- 4 days ago - Gilead sees Q2 EPS hit from IPR&D expenses - Seeking Alpha
- 6 days ago - AHF: Gilead's Greed Costs Latin America HIV Protection - Business Wire
- 6 days ago - Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million - Benzinga